T-Cell Depletion Therapy May Benefit Older Kidney Transplant Recipients

In a study of 111 kidney transplant recipients ≥50 years of age who received rabbit antithymocyte globulin (rATG) or interleukin 2 receptor antagonists (IL-2RA) in addition to tacrolimus, mycophenolate mofetil, and corticosteroids, patients who received rATG had a trend toward lower acute rejection rates, fewer readmissions, and fewer supratherapeutic tacrolimus troughs, with similar rates of infections. Quality-of-life analyses demonstrated that patients who received rATG were more likely to experience improvements in physical and social functioning posttransplantation. The Clinical Transplantation findings suggest that T-cell depletion in older transplant recipients may be beneficial.

Category:
Subcategory:
Body:

In a study of 111 kidney transplant recipients ≥50 years of age who received rabbit antithymocyte globulin (rATG) or interleukin 2 receptor antagonists (IL-2RA) in addition to tacrolimus, mycophenolate mofetil, and corticosteroids, patients who received rATG had a trend toward lower acute rejection rates, fewer readmissions, and fewer supratherapeutic tacrolimus troughs, with similar rates of infections. Quality-of-life analyses demonstrated that patients who received rATG were more likely to experience improvements in physical and social functioning posttransplantation. The Clinical Transplantation findings suggest that T-cell depletion in older transplant recipients may be beneficial.

Area(s) of Interest: